Change over period: —
NSE · VAISHALI
Vaishali Pharma Ltd
-25.9% from the 52-week high · +47.1% above the low
Vaishali Pharma Ltd. is a healthcare company, which engages in the marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2017-08-22. The firm is engaged in dealing in pharmaceutical ingredient, pharmaceutical formulations, surgical products, herbal and nutraceutical products, veterinary supplements operating in domestic and export market. In domestic markets, it is engaged in contract manufacturing and trading of active pharmaceuticals ingredient's (APIs) and supply of API's for export captive consumption. In export markets, it is engaged in manufacturing and export of pharmaceutical formulations; manufacturing and export of surgical products; manufacturing and export of veterinary products; and manufacturing and export of herbal and nutraceuticals products. Its product categories include API, formulation brands, formulations, herbal, nutraceuticals, oncology, surgical and veterinary, among others. The firm markets approximately 400 products in domestic and APIs has a product portfolio of more than 1,000 products for the overseas market.
The short version. Vaishali Pharma Ltd reported revenue of ₹30 crore for Sep 2026, down 9.1% from a year earlier. Net profit was ₹2 crore (up 100.0% year on year). Return on equity was 6.0% in Mar 2026. Promoter holding was 31.61% in Sep 2026, up 5.29 points over 8 quarters.
1 · The price
How has the stock traded?
Vaishali Pharma Ltd trades 25.9% below its 52-week high and 47.1% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹30 cr.
Sep 2026 net profit of ₹2 cr.
3.3 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Revenue | 30 | 23 | 27 | 25 | 33 |
| Net profit | 2 | 2 | 0 | 1 | 1 |
| Net margin % | 6.8 | 6.8 | 1.4 | 5.3 | 3.5 |
| EPS (₹) | 0.16 | 0.12 | 0.03 | 0.1 | 0.11 |
Annual
| FY2026 | |
|---|---|
| Revenue | 109 |
| Net profit | 4 |
| Net margin % | 3.8 |
| EPS (₹) | 0.32 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 6.0% in Mar 2026; debt to equity is 0.27.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 6.0 | — | — | — |
| Return on capital % | 9.8 | — | — | — |
| EBITDA margin % | 7.1 | — | — | — |
| Net margin % | 3.7 | — | — | — |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Up 5.29 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 26.32 | 26.32 | 26.32 | 26.32 | 31.61 | 31.61 | 31.61 | 31.61 | +5.29 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 73.68 | 73.68 | 73.68 | 73.68 | 68.39 | 68.39 | 68.39 | 68.39 | -5.29 |
Mutual fund holdings · Oct 2026
0 schemes hold this stock
0 the month before.
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for Vaishali Pharma Ltd are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about Vaishali Pharma Ltd
What is the Vaishali Pharma Ltd share price?
Vaishali Pharma Ltd (VAISHALI) last closed at ₹7.10, down 1.11% on the day. Its 52-week range is ₹4.88 to ₹9.69.
What is the market cap of Vaishali Pharma Ltd?
Vaishali Pharma Ltd has a market capitalisation of about ₹94 crore. Its price-to-earnings ratio is 9.5.
How are Vaishali Pharma Ltd's latest results?
Vaishali Pharma Ltd reported revenue of ₹30 crore for Sep 2026, down 9.1% from a year earlier. Net profit was ₹2 crore (up 100.0% year on year). Return on equity was 6.0% in Mar 2026. Promoter holding was 31.61% in Sep 2026, up 5.29 points over 8 quarters.
Who owns Vaishali Pharma Ltd?
As of Sep 2026, shareholding was: Promoter 31.61%, Public 68.39%.
How many mutual funds hold Vaishali Pharma Ltd?
0 mutual fund schemes held Vaishali Pharma Ltd in October 2026. That compares with 0 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 15 Oct 2024 · Stock Split From Rs.10/- to Rs.2/-
- 15 Oct 2024 · Bonus issue 1:1
- 17 Oct 2019 · Bonus issue 3:5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.